Skip to main content
. 2013 Dec 15;2013:125080. doi: 10.1155/2013/125080

Table 3.

Hormone levels in female cancer survivors classified to the high risk group.

Analyzed HR group n Hormones X M SD P
HL rtx − 12 FSH (mIU/mL) 7.07 7.0 2.78 0.647
HL rtx + 10 8.53 6.9 3.25 0.045
BMT 6 42.55 42.55 26.55 0.034
Solid tumors 9 10.55 7.9 14.68 0.068
Control 34 5.35 5.15 1.89

HL rtx − LH (mIU/mL) 6.13 3.85 6.67 0.283
HL rtx + 3.63 3.00 2.05 0.483
BMT 26.31 15.20 28.23 0.001
Solid tumors 6.45 7.0 5.93 0.494
Control 5.52 4.68 4.1

HL rtx − E2 (pg/mL) 69.72 42.79 101.82 0.628
HL rtx + 47.34 33.09 32.24 0.578
BMT 26.25 22.74 17.26 0.021
Solid tumors 40.91 17.6 47.29 0.670
Control 53.32 47.39 41.14

HL rtx − AMH (pmol/L) 23.17 25.10 15.25 0.042
HL rtx + 14.15 11.90 8.10 0.037
BMT 3.37 2.62 2.32 0.001
Solid tumors 19.21 8.14 16.30 0.05
Control 27.03 25.26 12.31

HR: high risk, HL: Hodgkin lymphoma, rtx: radiotherapy, BMT: bone marrow transplantation, FSH: follicle-stimulating hormone, LH: luteinizing hormone, E2: estradiol, AMH: anti-Müllerian hormone, X: average value, and M: median.